Fractyl raises series E funding of USD 55 million for diabetes cure

By Nikita Chaurasia  | Date: 2020-08-10

Fractyl raises series E funding of USD 55 million for diabetes cure

Fractyl Laboratories raised series E funding of USD 55 million to continue financing the pivotal clinical trial of its potential non-surgical, non-drug treatment for Type 2 diabetes.

As per the trusted sources, the capital will be invested on mass-based startup’s Revita T2Di pivotal clinical trial of Revita DMR. Revita is observing the effect of Fractyl’s Revita DMR treatment on insulin requirements and glycemic control.

Reportedly, the funding round was led by the new investor named Taiwania Capital Management Corporation. The financing also involved the existing investors like Emergent Medical Partners, Bessemer Venture Partners, Domain Associates, True Ventures, General Catalyst, Mithril Capital Management, and GV. The funding round included first time commitments from CDIB Venture Capital Corp., Catalio Capital Management, and YJ Capital.

Michael Huang, managing partner at Taiwania Capital Management Corporation, has reportedly stated that type 2 diabetes and NAFLD/NASH have adverse effects on people’s health across the world and account for majority global healthcare expenditure. He further added that Fractyl has carried out studies which reveal Revita’s potential to enhance the outcomes of the treatment for type 2 diabetes.

Fractyl’s co-founder and CEO Harith Rajagopalan states that Fractyl’s mission is to treat diabetes type 2 in a better way by addressing its root cause, that can reverse the disease process rather than managing its symptoms. He said that they now have database of hundreds of patients who suffered from type 2 diabetes and have shown long term benefits of a single Revita treatment.

Rajagopalan added that he welcomes the new investors and the continued support of the returning investors who saw that they have the potential to redefine the treatment for metabolic diseases like NAFLD/NASH and type 2 diabetes.

The company is looking forward to beginning with their pivotal U.S. clinical trial later this year.

Source credits-

https://www.massdevice.com/fractyl-adds-55m-for-type-2-diabetes-pivotal-trial/

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Russia denies plans of blocking YouTube & cutting off from the internet

Russia denies plans of blocking YouTube & cutting off from the internet

By Nikita Chaurasia

The Digital Development Minister of Russia has reportedly stated that the country is not planning to block Google’s video streaming platform YouTube as such a move would affect its users and will therefore be avoided.  It is worth notin...

Indian food delivery giant Swiggy to buy Dineout from Times Internet

Indian food delivery giant Swiggy to buy Dineout from Times Internet

By Nikita Chaurasia

Swiggy, an Indian food delivery giant, has recently announced an agreement with Times Internet to buy Dineout, a dining and restaurant technology platform. Swiggy will use the acquisition to enter the dining out (non-delivery) market, where it will c...

Grocery delivery platform Instacart files for U.S. stock market debut

Grocery delivery platform Instacart files for U.S. stock market debut

By Nikita Chaurasia

Instacart, a grocery delivery service, has announced that it has submitted a provisional registration statement with the Securities and Exchange Commission (SEC), clearing the way for the company to list its shares on the U.S. stock exchange. The ...

Tyson Foods improves annual sales outlook as meat prices surge in U.S.

Tyson Foods improves annual sales outlook as meat prices surge in U.S.

By Nikita Chaurasia

American food major Tyson Foods Inc. has reportedly improved its full-year sales outlook after witnessing better-than-expected earnings and revenue in the last quarter. The company raised its full-year sales to around USD 54 billion, above the averag...

EU likely to enforce new rules to regulate tech giants in spring 2023

EU likely to enforce new rules to regulate tech giants in spring 2023

By Nikita Chaurasia

The Executive Vice President of the European Commission Margrethe Vestager reportedly claimed that the union is likely to start enforcing the Digital Markets Act (DMA) in the spring of 2023. The antitrust legislation, which aims to limit the power of...